Parkinson’s

Parkinson's disease is a neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra. Parkinson's disease has four main symptoms such as tremor (trembling) in hands, arms, legs, jaw, or head, stiffness of the limbs and tru...

NICE recommends Pfizer’s Vizimpro for treating NSCLC Not long ago, Pfizer’s Vizimpro (dacomitinib) a tyrosine kinase inhibitor (TKI), was approved as a first-line monotherapy treatment for adult patients living with locally advanced or metastatic non-small lung cancer (NSCLC). As evaluated by the American Cancer...

Parkinson's Awareness Month April marks Parkinson's Awareness Month, is an occasion to spread awareness about Parkinson’s. Not the early signs as they are more than just any tremor! Parkinson’s changes everything. Over 10 Million people are living with Parkinson’s worldwide yet the condition remains a mystery. ...

Parkinson's Disease (PD) is a chronic and progressive movement disorder which primarily affects dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.  These neurons are usually responsible for the control and coordination process, which during the neuron malfuncti...

A group of researchers has recently discovered that an immune mechanism responsible in clearing bacterial infections may also be involved in causing Parkinson's disease. The study has identified the role of protein LRRK2 in tuberculosis, results have shown that it behaves similarly in Parkinson disease. This finding...

Merck and Eisai has entered into an Oncology Pact worth Up to USD 5.76 Billion Two major pharmaceutical companies (Merck & Eisai) has entered into a USD 5.76 Billion pact to develop and commercialize Lenvima (lenvatinib mesylate) both as a monotherapy and an in-combination therapy for treating multiple types of ...

Malaysia calls for phase 4 Dengvaxia study before considering full approval Already struggling to meet initial expectations, Sanofi Pasteur's dengue vaccine Dengvaxia will have to undergo phase 4 testing in Malaysia before the endemic country agrees to sign off on a full approval. Malaysia’s National Pharmaceutical ...

The South San Francisco biotech startup, Denali Therapeutics, that had raised $217 million last year to fight Alzheimer’s, Parkinson’s and ALS, and an additional  $130 million from investors in a private placement led by Baillie Gifford, a UK-based mutual fund, has finally spoken about its plans to use the fund. The...

Gene Therapy: The “Hunt” for CNS disorders! Many companies have tried over the years to find a way to reverse the course of crippling central nervous system disorders like amyotrophic lateral sclerosis (a.k.a. Lou Gehrig’s disease) but have failed. Fortunately, Gene therapy has proven to be an answer to a wide ran...